Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with TACE for unresectable hepatocellular carcinoma
ChiCTR-IIR-17013362Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: time to progression. Started Dec 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-IIR-17013362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013362.